Dose Table
See Sialanar®’s dosing table in full.
This content is intended for UK & ROI healthcare professionals. Not a healthcare professional? Return to audience selector.
Care should be taken when moving from another type of anticholinergic drug due to the potential for increased risk of anticholinergic adverse effects.1 There is no available data to support transferring patients from a non-glycopyrronium bromide anticholinergic (e.g. hyoscine/scopolamine or atropine) to Sialanar®.1,2
A washout period from the first drug should be considered. Sialanar® should be prescribed following the dose titration table, starting from dose level 1 to balance efficacy and side effects.2
The half-life of free scopolamine is approx. 10 hours so the drug should be cleared within about 72 hours. However, the ultimate decision as to when to start the second drug and the appropriate starting dose should lie with the treating clinician.2
Oral preparations of glycopyrronium bromide are not interchangeable on a microgram-for-microgram basis due to differences in bioavailability. Care should be taken if switching between oral preparations and dosing adjusted accordingly.3
Please follow the links below to find documents providing guidance on the equivalent doses of Sialanar® (2mg/5ml glycopyrronium bromide) oral solution1 and different generic glycopyrronium bromide oral solutions4-7
See Sialanar®’s dosing table in full.
Head to this section for guidance on side effects and titration.
Glycopyrronium has demonstrated lower rates of problematic side effects8 and treatment cessation8,9 vs. hyoscine.
UK-SIA-25-0065 | October 2025
Adverse Event Reporting Information
UK: Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Republic of Ireland: Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited. Phone: +44 333 200 1866 E-Mail: medinfo@proveca.com